Fred Hutchinson Cancer Research Center Clinical Research Associate Member University of Washington School of Medicine Pediatrics Associate Professor | |
QualificationsM.D., University of Minnesota, Medicine, 1984. B.A., Saint Olaf College, 1979. Expertise and Research InterestsHematopoietic cell transplant (HCT) is the only curative therapy for many life-threatening hematologic diseases, and theoretically could cure other chronic hematologic and immunologic disorders. The research projects under Dr. Woolfrey’s direction are aimed toward improving the effectiveness of hematopoietic cell transplants, particularly for patients with nonmalignant disorders. These studies explore the use of lower dose (nonmyeloablative) conditioning regimens to reduce the short and long term toxicities associated with HCT, the use of HCT to restore normal immunity in patients with HIV or refractory autoimmune diseases, and the use of alternative donors, including unrelated and mismatched related donors.
Clinical Studies 1. Nonmyeloablative conditioning regimen using low-dose total body irradiation with or without fludarabine for treatment of immune deficiencies, metabolic storage diseases, hemaglobinopathies, and other inherited disorders. The primary goal of each study is to determine whether establishment of stable mixed chimerism using a low-toxicity regimen results in amelioration of the disease, as an alternative to standard transplant procedures.
2. Nonmyeloablative conditioning regimen using low-dose total body irradiation and fludarabine for treatment of HIV. The primary goal is to determine whether immunity can be reconstituted in HIV patients using a non-toxic regimen for HCT. A second goal is to establish a method for allogeneic transplant that is tolerated by patients with HIV for cure of life-threatening malignancies.
3. High-dose immunoablative therapy followed by autologous HCT for treatment of refractory autoimmune disorders. The primary goal is to determine whether immune ablation followed by rescue with purified autologous stem cells could result in restoration of immunity without recurrence of the autoreactive T cells. Patients eligible include children with juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, or dermatomyositis.
4. Use of haploidentical donors for HCT in the treatment of life-threatening hematologic diseases in children. The goal of these studies has been to determine the outcome of transplants for patients who undergo HCT using haploidentical donors.
Other ExpertiseHematology Oncology Pediatrics Medicine Bone Marrrow Transplantation Hematopoietic Cell Transplantation Immunology Future ResearchImmune Reconstitution Tolerance HIV Juvenile Rheumatoid Arthritis
KeywordsCOS Keywords:Bone Marrow Transplantation, Hematology, Immunology, Oncology, Pediatrics.Languages(Reading, Writing, Speaking)English: (Fluent, Fluent, Fluent) MembershipsAmerican Society for Blood and Marrow Transplantation American Society of Hematology Society for Leukocyte Biology Society for Pediatric Research Honors and Awards1994, American Cancer Society Young Investigator Honored Presentation,
American Cancer Society
1984, Minnesota Medical Foundation Undergraduate Research Award,
1978, Honors Program,
Cambridge University, Cambridge, England
Previous Positions2003, Associate Professor,
University of Washington,
School of Medicine,
Pediatrics
2002, Associate Member,
Fred Hutchinson Cancer Research Center,
Pediatric Bone Marrow Transplantation and Immunogenetics,
Clinical Research Division
2000-2003, Assistant Professor,
University of Washington,
School of Medicine,
Pediatrics
1996-2002, Assistant Member,
Fred Hutchinson Cancer Research Center,
Pediatric Bone Marrow Transplantation and Immunogenetics
1996-2002, Acting Assistant Professor,
University of Washington,
School of Medicine,
Pediatrics
1995-1995, Director,
Yale University,
School of Medicine,
Pediatrics,
Pediatric Stem Cell Program
1995-1995, Instructor,
Yale University,
School of Medicine,
Pediatrics
1994-1994, Associate in Clinical Research,
Fred Hutchinson Cancer Research Center,
Clinical Transplantation Support,
Clinical Research Division
1992-1995, Senior Research Fellow,
Fred Hutchinson Cancer Research Center and Virginia Mason Research Center
Publications- Mielcarek M, Sandmaier BM, Maloney DG, Maris M, McSweeney PA, Woolfrey A, Chauncey T, Feinstein L, Niederwieser D, Blume KG, Forman S, Torok-Storb B, Storb R, Nonmyeloablative hematopoietic cell transplantation: status quo and future
perspectives, Journal of Clinical Immunology, 22(2), 70-4, March 2002
 - Woolfrey AE, Anasetti C, Storer B, Doney K, Milner LA, Sievers EL, Carpenter P, Martin P, Petersdorf E, Appelbaum FR, Hansen JA, Sanders JE, Factors associated with outcome after unrelated marrow transplantation for
treatment of acute lymphoblastic leukemia in children, Blood, 99(6), 2002-8, March 2002
 - Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C, Major-histocompatibility-complex class I alleles and antigens in
hematopoietic-cell transplantation, The New England Journal of Medicine, 345(25), 1794-800, December 2001
 - Woolfrey A, Pulsipher MA, Storb R, Nonmyeloablative hematopoietic cell transplant for treatment of immune
deficiency, Current Opinion in Pediatrics, 13(6), 539-45, December 2001
 - Anasetti C, Petersdorf EW, Martin PJ, Woolfrey A, Hansen JA, Trends in transplantation of hematopoietic stem cells from unrelated
donors, Current Opinion in Hematology, 8(6), 337-41, November 2001
 - Petersdorf E, Anasetti C, Martin PJ, Woolfrey A, Smith A, Mickelson E, Malkki M, Lin MT, Hansen JA, Genomics of unrelated-donor hematopoietic cell transplantation, Current Opinion in Immunology, 13(5), 582-9, October 2001
 - Benito AI, Milner LA, Leisenring W, Deeg HJ, Woolfrey AE, Absence of major histocompatibility class II expression does not impair
hematopoiesis in mice, Experimental Hematology, 29(9), 1070-5, September 2001
 - Maris M, Woolfrey A, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R, Nonmyeloablative hematopoietic stem cell transplantation: transplantation
for the 21st century, Frontiers in Bioscience [electronic Resource] : a Journal and Virtual Library, 6, G13-6, August 2001
 - Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R, Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose
cytotoxic therapy by the graft-versus-tumor effect, Annals of the New York Academy of Sciences, 938, 328-37; discussion 3, June 2001
 - Rocha V, Cornish J, Sievers EL, et al, Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia, Blood, 97(10), 2962-71, May 2001
 - Petersdorf EW, Gooley T, Malkki M, Anasetti C, Martin P, Woolfrey A, Smith A, Mickelson E, Hansen JA, The biological significance of HLA-DP gene variation in haematopoietic
cell transplantation, British Journal of Haematology, 112(4), 988-94, March 2001
 - Anasetti C, Petersdorf EW, Martin PJ, Woolfrey A, Hansen JA, Transplantation of hematopoietic stem cells from unrelated volunteer donors, Transplantation Proceedings, 32(7), 1539-40, November 2000
 - Sierra J, Bjerke J, Hansen J, Martin P, Petersdorf E, Woolfrey A, Anasetti C, Marrow transplants from unrelated donors as treatment for acute leukemia, Leukemia and Lymphoma, 39(5-6), 495-507, November 2000
 - Anasetti C, Petersdorf EW, Martin PJ, Woolfrey A, Hansen JA, Improving availability and safety of unrelated donor transplants, Current Opinion in Oncology, 12(2), 121-6, March 2000
 - Mickelson EM, Petersdorf E, Anasetti C, Martin P, Woolfrey A, Hansen JA, HLA matching in hematopoietic cell transplantation, Human Immunology, 61(2), 92-100, February 2000
 - Petersdorf EW, Mickelson EM, Anasetti C, Martin PJ, Woolfrey AE, Hansen JA, Effect of HLA mismatches on the outcome of hematopoietic transplants, Current Opinion in Immunology, 11(5), 521-6, October 1999
 - Storb R, Yu C, Sandmaier BM, McSweeney PA, Georges G, Nash RA, Woolfrey A, Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting, Annals of the New York Academy of Sciences, 872, 372-5; discussion 37, 1999
 - Degar BA, Harrington RD, Rappeport JM, Woolfrey AE, 13-cis-retinoic acid-induced eosinophilia following autologous bone marrow transplantation for neuroblastoma, Medical and Pediatric Oncology, 32(4), 308-10, April 1999
 - Storb R, Yu C, Sandmaier B, McSweeney P, Georges G, Nash R, Woolfrey A, Mixed hematopoietic chimerism after hematopoietic stem cell allografts, Transplantation Proceedings, 31(1-2), 677-8, 1999
 - Woolfrey A, Anasetti C, Allogeneic hematopoietic stem-cell engraftment and graft failure, Pediatric Transplantation, 3 Suppl 1, 35-40, 1999
 - Woolfrey AE, Anasetti C, Petersdorf EW, Martin PJ, Sanders JE, Hansen JA, Unrelated donor marrow transplantation for treatment of childhood hematologic malignancies-effect of HLA disparity and cell dose, Cancer Treatment and Research, 101, 25-51, 1999
 - Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA, Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient, Blood, 92(10), 3515-20, 1998
 - Woolfrey AE, Gooley TA, Sievers EL, Milner LA, Andrews RG, Walters M, Hoffmeister P, Hansen JA, Anasetti C, Bryant E, Appelbaum FR, Sanders JE, Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome, Blood, 92(10), 3546-56, 1998
 - Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC, Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population, Blood, 92(3), 737-44, 1998
 - Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C, Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase, Blood, 92(2), 394-401, 1998
 - Harrington RD, Woolfrey AE, Bowden R, McDowell MG, Hackman RC, Legionellosis in a bone marrow transplant center, Bone Marrow Transplantation, 18(2), 361-8, August 1996
 - Harrington RD, Lewis CG, Aslanzadeh J, Stelmach P, Woolfrey AE, Oerskovia xanthineolytica infection of a prosthetic joint: case report and review, Journal of Clinical Microbiology, 34(7), 1821-4, July 1996
 - Woolfrey AE, Nepom GT, Differential transcription elements direct expression of HLA-DQ genes, Clinical Immunology and Immunopathology, 74(2), 119-26, February 1995
 - Woolfrey AE, Andersen LC, Shewey L, Chung J, Nepom GT, Analysis of differential HLA-DQB expression in autologous B cell lines, Journal of Leukocyte Biology, 53(6), 697-706, June 1993
 - Woolfrey AE, Neudorf S, Filipovich AH, Comparison of two immuno-mechanical methods of T-cell depletion of human bone-marrow for prevention of graft-versus-host disease: soybean lectin agglutination and sheep erythrocyte rosette depletion v, Thymus, 7(6), 327-34, 1985

Profile DetailsCOS Expertise ID #1056139 Individual Expertise profile of Ann Woolfrey, Copyright Ann Woolfrey. © COS Expertise TM, 2009, ProQuest LLC All rights reserved. |